Skip to main content
RT @drdavidliew: Pilot vagal nerve stimulation for RA: interesting with clinical and immunological response, but surgica

David Liew drdavidliew

7 years 4 months ago
Pilot vagal nerve stimulation for RA: interesting with clinical and immunological response, but surgical complications and lack of imaging data as yet. Also 4x/day worse than daily: too often might breed resistance? Looking forward to seeing more #EULAR2019 LB0009 @RheumNow https://t.co/VZCl0RBlbq
Saturday June 15th was the last half-day at EULAR 2019 but was highlighted by the “late-breaking” (LB) presentations that were presented from the podium and by poster. Below are the top “LB” presentations from EULAR this year:
Safety and Immunogenicity is one of nine educational videos available in the "Therapeutic Update: Biosimilars in Rheumat

Dr. John Cush RheumNow

7 years 4 months ago
Safety and Immunogenicity is one of nine educational videos available in the "Therapeutic Update: Biosimilars in Rheumatology" video series, sponsored by Sandoz, Inc. and now available on RheumNow. https://t.co/1vmnEJqOSi #sponsored #biosimilars
Dr. Dinesh Khanna discusses the pulmonary outcomes of tocilizumab is systemic sclerosis (focuSSed trial). #EULAR2019 O

Dr. John Cush RheumNow

7 years 4 months ago
Dr. Dinesh Khanna discusses the pulmonary outcomes of tocilizumab is systemic sclerosis (focuSSed trial). #EULAR2019 OP0245 https://t.co/KvxoPhvyS6
RT @sclerodermaUM: Presentation today at ATS #ATS2019. 1. early diffuse SSc. 2. 64% have ILD-recruited for elevated acut

Dr. Dinesh Khanna sclerodermaUM

7 years 4 months ago
Presentation today at ATS #ATS2019. 1. early diffuse SSc. 2. 64% have ILD-recruited for elevated acute phase reactants. 3. treated with Tocilizumab vs. placebo for 48 wks EARLY SSc; elevated acute phase reactants; anti-IL-6 inhibition--> PRESERVATION OF ILD https://t.co/63lwR1G0Cp
RT @sclerodermaUM: Going beyond scleroderma. 1. Tanezumab is effective for OA related pain and no new safety concerns.

Dr. Dinesh Khanna sclerodermaUM

7 years 4 months ago
Going beyond scleroderma. 1. Tanezumab is effective for OA related pain and no new safety concerns. #EULAR2019 https://t.co/Uohex1uybS
RT @sclerodermaUM: Low dose rituximab for retreatnent of RA. —6 month trial —RCT 1000 mg or 500 mg or 200 mg single

Dr. Dinesh Khanna sclerodermaUM

7 years 4 months ago
Low dose rituximab for retreatnent of RA. —6 month trial —RCT 1000 mg or 500 mg or 200 mg single dose. —there were more flares with low dose but less SI. — DAS 28 response was similar #EULAR2019
RT @tuna0sashimi: Exercise program 30 min 12w (combination of generalised upper limb and specific hand exercises) helps

Alberta Hoi tuna0sashimi

7 years 4 months ago
Exercise program 30 min 12w (combination of generalised upper limb and specific hand exercises) helps to improve pain, function, dexterity, QOL over time more so than controlled group #eular2019 @RheumNow
RT @tuna0sashimi: MTX withdrawal in tofacitinib MR 11mg ORAL shift 1y study @week 24, MTX blindly withdrawal for pt achi

Alberta Hoi tuna0sashimi

7 years 4 months ago
MTX withdrawal in tofacitinib MR 11mg ORAL shift 1y study @week 24, MTX blindly withdrawal for pt achieved LDA (CDAI <=10) n>200 each arm no difference between arms consistent with anecdotal evidence of how pt can withdraw MTX in real life. #eular2019 @RheumNow
RT @sclerodermaUM: Vagal nerve stimulation for management of RA. Effective in refractory RA #EULAR2019 https://t.co/petE

Dr. Dinesh Khanna sclerodermaUM

7 years 4 months ago
Vagal nerve stimulation for management of RA. Effective in refractory RA #EULAR2019 https://t.co/petEUKty7v
RT @tuna0sashimi: Please please publish this so we can quote it for our patients RT @CreakyJoints: Reassuring news about

Alberta Hoi tuna0sashimi

7 years 4 months ago
Please please publish this so we can quote it for our patients RT @CreakyJoints: Reassuring news about hair loss and methotrexate: a #EULAR2019 study of around 100 #RA patients found there was minimal hair loss related to MTX therapy. https://t.co/vHis3KZhbz
RT @tuna0sashimi: #eular2019 H2H abatacept vs adalimumab prev study “AMPLE” showed similar efficacy (single blinded

Alberta Hoi tuna0sashimi

7 years 4 months ago
#eular2019 H2H abatacept vs adalimumab prev study “AMPLE” showed similar efficacy (single blinded RA <2y study). Now “Early AMPLE” study for seropositive RA with or without HLA shared epitope confirmed previous observation of superiority of ABA at 24w
×